Drug intelligence / Profile preview

RSVI-306

Development stage: Preclinical
Lead developer: RosVivo Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

RSVI-306 is an experimental microRNA-based therapeutic candidate being developed by RosVivo Therapeutics for the treatment of COVID-19. Public reports describe RSVI-305/306 as next‑generation miRNA drugs aimed at viral infections such as SARS‑CoV‑2, extending RosVivo’s miRNA platform that has shown disease-modifying potential in metabolic disorders like diabetes through long-acting, low–side effect modulation of pathogenic pathways in preclinical studies.[1][5][7] RSVI-306 is currently in the preclinical stage, and detailed information on its specific miRNA sequence, direct molecular targets, delivery system, and dosing has not yet been disclosed.

Other names: RSVI-306RSVI306RSVI 306

Beyond the preview

Go deeper on RSVI-306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSVI-306.

Explore the full profile